Cormorant Asset Management’s Seres Therapeutics MCRB Stock Holding History

Cormorant Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-12,653	Closed	-$7.35M	–	87
2016 Q2	$7.35M	Buy	12,653 +153	+1%	+$89.8K	1.04%	35
2016 Q1	$6.64M	Hold	12,500	–	–	1%	36
2015 Q4	$8.77M	Hold	12,500	–	–	1.05%	33
2015 Q3	$7.41M	Buy	12,500 +10,000	+400%	+$8.16M	1.18%	31
2015 Q2	$2.08M	Buy	+2,500	New	+$2.18M	0.28%	62

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cormorant Asset Management's MCRB Position: Q3 2016 in Review

Cormorant Asset Management sold out of Seres Therapeutics (MCRB) in Q3 2016, closing a stake of 12,653 shares — an estimated $7.35M sold.

Cormorant Asset Management first reported a position in MCRB in Q2 2015 and held it in 5 quarters. The position peaked at $8.77M in Q4 2015. 94 funds tracked by Wall St. Rank hold MCRB as of Q3 2016.

Cormorant Asset Management reported no remaining Seres Therapeutics position as of Q3 2016 after selling out during the quarter.
Cormorant Asset Management sold 12,653 Seres Therapeutics shares in Q3 2016, an estimated $7.35M.
Cormorant Asset Management first reported a position in Seres Therapeutics in Q2 2015 and held it in 5 quarters.
Cormorant Asset Management's Seres Therapeutics position peaked at $8.77M in Q4 2015.
94 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2016.

Based on Cormorant Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.